Moleculin Biotech (NASDAQ:MBRX) Upgraded to “Buy” at Maxim Group

Moleculin Biotech (NASDAQ:MBRX) was upgraded by analysts at Maxim Group from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a $4.00 price objective on the stock. Maxim Group’s target price would indicate a potential upside of 273.83% from the company’s previous close.

A number of other analysts also recently weighed in on MBRX. StockNews.com started coverage on Moleculin Biotech in a report on Thursday, March 13th. They issued a “sell” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Moleculin Biotech in a research report on Monday.

Moleculin Biotech Stock Performance

Shares of NASDAQ MBRX opened at $1.07 on Tuesday. The firm has a 50 day moving average price of $1.32 and a two-hundred day moving average price of $1.99. Moleculin Biotech has a 52-week low of $0.40 and a 52-week high of $6.23.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.